23 Oct 2023 • Cardiovascular Disease and Diabetes Mellitus: How are they related?🤔

Hyperglycaemia is a risk factor for CVD and agreeably, CVD is a common comorbidity in T2DM.

What is the reason behind their ill-fated relationship? It is quite controversial.

Many agree that treatment of hyperglycaemia can alter a number of factors other than circulating glucose levels and hence, clinical and experimental data support the hypothesis that factors other than hyperglycaemia like LDL-cholesterol, triglycerides, blood pressure, and systemic inflammation may be the real culprit.🫀

So, what is the reason behind this perplexity?

If glucose control was the primary driver of increased ASCVD in T2DM, then one would have expected insulin, sulfonylureas, and other glucose-reducing agents to reduce CVD events.

But contrary to popular belief, several large studies of T2DM have failed to prove the benefits of glucose reductions in these patients. 💉

However, there are many who disagree with this argument since they believe it is supported by several “failed” clinical trials.

Amidst all these arguments, the accepted verdict is that the benefit of improved glycemic control on ASCVD appears to be multifactorial and fails to prove cause and effect.

The influence of glucose reduction in ASCVD prevention remains elusive till date and who better than a panel of experts in the field to break it down for you! 👩🏻‍⚕👨🏻‍⚕

Join us at RCP Cardiology with well-renowned and celebrated cardiologist, Dr. Jamshed Dalal as he answers all your queries at the Panel discussion on Diabetes Mx in ASCVD: Benefits in Heart Failure and beyond

Click here to reserve your seat now!🎟️